Sign In
Buy CNTA
$40.50
+0 (+0%)
At Close: Jul 23, 2026
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Recommendation of “Buy” from Brokerages
02:22am, Monday, 23'rd Mar 2026
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA - Get Free Report) has been assigned an average recommendation of "Buy" from the thirteen ratings firms that are covering the company, Marketbe
Insider Selling: Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Sells $1,927,250.68 in Stock
04:21am, Monday, 16'th Mar 2026
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA - Get Free Report) insider Gregory Weinhoff sold 73,196 shares of the stock in a transaction on Friday, March 13th. The shares were sold at an
Centessa Pharmaceuticals Teases ORX750 Phase II Update, Registrational Study Start at Conference
02:02am, Tuesday, 10'th Mar 2026
Centessa Pharmaceuticals (NASDAQ: CNTA) used remarks at a healthcare conference to highlight recent progress in its orexin agonist program and outline near-term priorities that include a Phase II upda
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
03:03am, Thursday, 05'th Mar 2026
Tokyo, Japan and Cambridge, UK, 5 March 2026 - Nxera Pharma Co. , Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development m
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50%
10:09am, Monday, 23'rd Feb 2026
Commodore Capital sold 1,850,000 shares of Centessa in the fourth quarter; the estimated trade value was $46.86 million. Meanwhile, the quarter-end position value decreased by $44.10 million, reflecti
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition
05:03pm, Thursday, 19'th Feb 2026
Connecticut-based Braidwell initiated a position of 2,188,320 Centessa shares in the fourth quarter. The quarter-end value of the position increased by $54.73 million, reflecting the new stake.
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
03:45am, Thursday, 12'th Feb 2026
Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development mil
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 03'rd Feb 2026
BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines
This Fund Locked In Gains With a $14.5 Million Biotech Exit Amid a Staggering Stock Rally
07:09pm, Sunday, 01'st Feb 2026
Tanager Wealth Management exited its entire CNTA position, reducing holdings by 598,044 shares in the fourth quarter. As a result, the quarter-end position value decreased by $14.50 million, reflectin
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Rating of “Moderate Buy” from Analysts
02:44am, Sunday, 01'st Feb 2026
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen analysts that are currently covering the firm, Marketbeat R
Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder Antidepressive effects and enhanced wakefulness were observe
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa
03:09am, Tuesday, 13'th Jan 2026
Tokyo, Japan and Cambridge, UK, 13 January 2026 - Nxera Pharma Co. , Ltd. ("Nxera" or "the Company"; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associate
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Rating of “Moderate Buy” by Brokerages
01:30am, Wednesday, 07'th Jan 2026
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA - Get Free Report) has received an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Mark
Critical Review: Centessa Pharmaceuticals (NASDAQ:CNTA) & Universe Pharmaceuticals (NASDAQ:UPC)
01:32am, Monday, 22'nd Dec 2025
Centessa Pharmaceuticals (NASDAQ: CNTA - Get Free Report) and Universe Pharmaceuticals (NASDAQ: UPC - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Recommendation of “Buy” from Analysts
01:16am, Saturday, 13'th Dec 2025
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA - Get Free Report) has been assigned an average recommendation of "Buy" from the thirteen analysts that are currently covering the firm, Market
